|
September 22, 2022
|
Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposium
|
|
September 7, 2022
|
New Preclinical Data for EDP-235, Enanta’s Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek™ 2022
|
|
September 1, 2022
|
Enanta Pharmaceuticals to Participate in Two Investor Conferences in September
|
|
August 8, 2022
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET
|
|
August 8, 2022
|
Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer
|
|
August 1, 2022
|
Enanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022
|
|
July 29, 2022
|
Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19
|
|
June 21, 2022
|
Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer
|
|
June 8, 2022
|
Enanta Pharmaceuticals Announces Data Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022
|
|
June 2, 2022
|
Enanta Pharmaceuticals to Participate in Two Investor Conferences in June
|